TFS Gulf 
Book 1:1 session with industry experts!
- UAE has just administered a powerful dose of reform to its pharmaceutical and healthcare industries.
- The new federal decree laws enforce strict regulation on medicines, medical devices, and cosmetics. And, if companies don’t comply, they could face fines of up to AED 1 million ($272,000).
- As of the 8th of August 2023, the UAE Government has announced the issuance of new regulations governing the practice of healthcare professionals.
What’s in the law?
The UAE’s new healthcare and pharmaceutical laws are about to set a new standard.
These rules cover everything from drug products, medical devices, dietary supplements, and even genetically modified items.
So, if you’re running a pharmacy in Dubai or a biotech startup in a free zone, you’re on the government’s radar.
Who’s affected?
The law applies to a wide range of entities, including:
- Pharmacies, medical warehouses, and manufacturing units.
- Biobanks, pharmaceutical laboratories, and clinical research centers.
- Even free-zone establishments, which often operate under different rules, will now come under its purview.
Penalties and Compliance
Compliance isn’t optional, and the penalties are steep:
Financial Fines for violations: AED 1,000 to AED 1 million ($272,000) for establishments; up to AED 500,000 for professionals.
Suspensions & Revocations: Non-compliance could lead to license suspensions of up to six months, or worse, permanent revocation.
Grace period for compliance: One year, with extensions possible through Cabinet approval.
And it doesn’t stop there.
A new Pharmaceutical Policies Committee will oversee pricing, monitoring, and distribution to ensure standards align with both national priorities and global benchmarks.
Also read: UAE Mandates Women’s Inclusion on Corporate Boards by 2025
What does this mean for the industry?
1. Global competitiveness: By implementing world-class standards, the UAE is positioning itself as a global hub for pharmaceutical innovation.
2. Improved quality control: With strict pharmacovigilance systems, patient safety will take center stage. Side effects and adverse reactions? Consider them cornered.
3. Fostering investment: The law is likely to attract both local and international investors, driving innovation and development within the pharmaceutical industry.
4. Enhanced access: A national medical inventory policy will track product availability, ensuring no patient has to worry about critical shortages.
Also read: Fake financial reports used by UAE companies to raise money
Wrapping up
The new decree could be a turning point for the UAE’s pharmaceutical and healthcare sectors:
- For Patients: Better access to safer, higher-quality treatments.
- For Investors: A more secure and attractive environment for funding medical research and innovation.
- For the UAE: A giant leap toward becoming a global leader in healthcare.
